Nuzenio

Tradingview Aurobindo Pharma

Tradingview Aurobindo Pharma entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 9 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Aurobindo Pharma rises 3% after Q1 profit beats estimates; HDFC Securities retains 'Add', TP Rs 1,730 - TradingViewTradingView · Fri, 07 Aug 2026 06:21:00 GMTAurobindo Pharma rises 3% after Q1 beat; HDFC Securities retains 'Add', Axis Securities cuts to 'Hold' - TradingViewTradingView · Fri, 07 Aug 2026 06:21:00 GMTAUROPHARMA: Revenue up 16% YoY, EBITDA margin at 21%, guidance for double-digit growth reaffirmed - TradingViewTradingView · Thu, 06 Aug 2026 05:41:00 GMTAurobindo Pharma Q1FY27 net profit jumps 25% to record Rs1,032 crore, on broad-based growth - TradingViewTradingView · Wed, 05 Aug 2026 17:35:45 GMTAUROPHARMA: Q1 FY27 saw robust revenue and profit growth, boosted by the Lannett acquisition and share buyback - TradingViewTradingView · Wed, 05 Aug 2026 14:39:59 GMTAUROPHARMA: Revenue up 16.3% and net profit up 25.2% year-over-year, driven by broad-based growth - TradingViewTradingView · Wed, 05 Aug 2026 14:31:07 GMTAurobindo Pharma Q1 Consol Net PAT 10.33 Billion Rupees - TradingViewTradingView · Wed, 05 Aug 2026 14:28:02 GMTAurobindo Pharma Shares Rise 2.01%, Trades at Rs 1,617.80 - TradingViewTradingView · Wed, 05 Aug 2026 05:48:00 GMT

Timeline

Fri, 07 Aug 2026 06:21:00 GMTAurobindo Pharma rises 3% after Q1 profit beats estimates; HDFC Securities retains 'Add', TP Rs 1,730 - TradingView
Fri, 07 Aug 2026 06:21:00 GMTAurobindo Pharma rises 3% after Q1 beat; HDFC Securities retains 'Add', Axis Securities cuts to 'Hold' - TradingView
Thu, 06 Aug 2026 05:41:00 GMTAUROPHARMA: Revenue up 16% YoY, EBITDA margin at 21%, guidance for double-digit growth reaffirmed - TradingView
Wed, 05 Aug 2026 17:35:45 GMTAurobindo Pharma Q1FY27 net profit jumps 25% to record Rs1,032 crore, on broad-based growth - TradingView
Wed, 05 Aug 2026 14:39:59 GMTAUROPHARMA: Q1 FY27 saw robust revenue and profit growth, boosted by the Lannett acquisition and share buyback - TradingView
Wed, 05 Aug 2026 14:31:07 GMTAUROPHARMA: Revenue up 16.3% and net profit up 25.2% year-over-year, driven by broad-based growth - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Aurobindo Pharma.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.